December 2015 Vol 8, No 9

As acquisition costs for inpatient-related drugs continue to climb, it is time to revisit the work of an important committee outside of the P&T structure, namely, the PharmacoEconomics and Clinical Effectiveness (PEACE) committee.
To the Editor: The study by Roy and colleagues (June 2015) presented a model framework to estimate the costs of treatment for relapsed and/or refractory multiple myeloma. We believe the assumptions applied in the study, particularly those regarding duration of therapy, lead to erroneous conclusions.
Chronic myelogenous leukemia (CML) is a hematologic cancer that occurs primarily in adults. Although CML can occur at any age, the median age at diagnosis is 64 years, and the incidence increases with age.
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
Many believe that proprotein convertase subtil­isin/kexin type 9 (PCSK9) inhibitors are the pharmacotherapeutic innovation of the decade for prevention of cardiovascular (CV) events.
In the past 5 years, there has been a large increase in the number of employers focused on effective ways to manage the rising cost of specialty drugs. At the same time, employers have been working hard to comply with the Affordable Care Act (ACA) and are cognizant of the expected excise tax.
For many years, disease­modifying antirheumatic drugs (DMARDs) have been the mainstay of RA treatment, reducing inflammation and preventing further joint deterioration and disease progression. In the past 15 years, biologic DMARDs have become available and have proved effective for reducing inflammation and managing the disease.
You Cannot Manage What You Cannot Measure

Results 1 - 6 of 6
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME